Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures

Li,Jianlin; Wang,Bing; Wang,Yue; Wu,Fei; Li,Panfeng; Li,Yang; Zhao,Lei; Cui,Wenjun; Ding,Yu; An,Qian; Si,Jiangtao

doi:10.3892/etm.2013.1061

Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures

Authors:
- Jianlin Li
- Bing Wang
- Yue Wang
- Fei Wu
- Panfeng Li
- Yang Li
- Lei Zhao
- Wenjun Cui
- Yu Ding
- Qian An
- Jiangtao Si
View Affiliations

Affiliations: Department of Vascular Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: April 10, 2013 https://doi.org/10.3892/etm.2013.1061
Pages: 1760-1764

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostaglandin E1 (PGE1) is widely used in the treatment of limb ischemia for its potent vasodilatory and antiplatelet effects. In order to assess the curative effect of liposomal PGE1 (lipo-PGE1) as an adjuvant to surgery in patients with acute lower limb ischemia (ALLI), 204 patients who underwent hybrid procedures (operative thromboembolectomy or bypass and necessary endovascular interventions) for ALLI were randomly divided into a blank control group and a lipo-PGE1 group (intravenous infusion of 20 µg/day for 12-14 consecutive days following surgery). Patients were followed-up for 6 months after surgical revascularization for clinical events. The primary study endpoint, which was the combined incidence of perioperative (30 days) mortality (POM) and major adverse limb events (MALE; amputation or major intervention), was significantly reduced in patients treated with lipo-PGE1 (5.1% compared with 13.2% in the control group). The overall incidence of clinical events, including POM, MALE and major adverse cardiovascular events, was significantly reduced in patients receiving lipo-PGE1 (8.2%) compared with the controls (20.8%). Hybrid procedures are an improved method for treating ALLI and may remedy underlying lesions of vessels following thromboembolectomy.

View Figures

View References

1.	Dormandy JA and Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 31:S1–S296. 2000.PubMed/NCBI
2.	Murota H, Kotobuki Y, Umegaki N, Tani M and Katayama I: New aspect of anti-inflammatory action of lipo-prostaglandin E1 in the management of collagen diseases-related skin ulcer. Rheumatol Int. 28:1127–1135. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Gao Y, Xu P, Chen L and Li Y: Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect. Int J Pharm. 387:263–271. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Brass EP, Anthony R, Dormandy J, et al: Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 43:752–759. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Gabriel A, Werba A, Mares P, Grubhofer G, Hrska F, Griesmacher A, et al: Influence of prostaglandin E1 on tissue ischemia during surgical repair of the abdominal aorta. J Cardiothorac Vasc Anesth. 2:201–206. 1996. View Article : Google Scholar : PubMed/NCBI
6.	Willerson JT, Yao SK, McNatt J, Cui K, Anderson HV, Swensen C, et al: Liposome-bound prostaglandin E1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation. 89:1786–1791. 1994. View Article : Google Scholar : PubMed/NCBI
7.	de Donato G, Gussoni G, de Donato G, Cao P, Setacci C, Pratesi C, et al: Acute limb ischemia in elderly patients: can iloprost be useful as an adjuvant to surgery? Results from the ILAILL study Eur J Vasc Endovasc Surg. 34:194–198. 2007.PubMed/NCBI
8.	Matsagkas M, Kouvelos G, Arnaoutoglou E, Papa N, Labropoulos N and Tassiopoulos A: Hybrid procedures for patients with critical limb ischemia and severe common femoral artery atherosclerosis. Ann Vasc Surg. 25:1063–1069. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Schrijver AM, Moll FL and De Vries JP: Hybrid procedures for peripheral obstructive disease. J Cardiovasc Surg (Torino). 51:833–843. 2010.PubMed/NCBI
10.	Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, et al: Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 50:1462–1473. el–e3. 2009. View Article : Google Scholar
11.	Katzen BT: Clinical diagnosis and prognosis of acute limb ischemia. Rev Cardiovasc Med. 3(Suppl 2): S2–S6. 2002.PubMed/NCBI
12.	Aune S and Trippestad A: Operative mortality and long-term survival of patients operated on for acute lower limb ischaemia. Eur J Vasc Endovasc Surg. 15:143–146. 1998. View Article : Google Scholar : PubMed/NCBI
13.	Braithwaite BD, Davies B, Birch PA, Heather BP and Earnshaw JJ: Management of acute leg ischaemia in the elderly. Br J Surg. 85:217–220. 1998. View Article : Google Scholar : PubMed/NCBI
14.	Nypaver TJ, Whyte BR, Endean ED, Schwarcz TH and Hyde GL: Nontraumatic lower-extremity acute arterial ischemia. Am J Surg. 176:147–152. 1998. View Article : Google Scholar : PubMed/NCBI
15.	Pemberton M, Varty K, Nydahl S and Bell PR: The surgical management of acute limb ischaemia due to native vessel occlusion. Eur J Vasc Endovasc Surg. 17:72–76. 1999. View Article : Google Scholar : PubMed/NCBI
16.	Lipsitz EC, Veith FJ and Wain RA: Digital fluoroscopy as a valuable adjunct to open vascular operations. Semin Vasc Surg. 16:280–290. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Bosma HW and Jörning PJ: Intra-operative arteriography in arterial embolectomy. Eur J Vasc Surg. 4:469–472. 1990. View Article : Google Scholar : PubMed/NCBI
18.	Zaraca F, Stringari C, Ebner JA and Ebner H: Routine versus selective use of intraoperative angiography during thromboembolectomy for acute lower limb ischemia: analysis of outcomes. Ann Vasc Surg. 24:621–627. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio RD and De Caterina R: Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J. 142:733–739. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Shin M, Song SH, Kim JM, Kim SJ, Joh JW, Lee SK, et al: Effectiveness of intraportal prostaglandin E1 administration after liver transplantation. Transplant Proc. 44:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Mitate E, Sasaguri M, Oobu K, Mitsuyasu T, Tanaka A, Kiyosue T and Nakamura S: Postoperative changes of blood flow in free microvascular flaps transferred for reconstruction of oral cavity: effects of intravenous infusion of prostaglandin E1. Asian J Oral Maxillofacial Surg. 23:113–116. 2011. View Article : Google Scholar
22.	Sim AK, McCraw AP, Cleland ME, Aihara A, Otomo S, Hosoda K, et al: A preclinical assessment of the effect of lipo-PGE1 on thrombus formation and thrombus disaggregation. Adv Drug Deliv Rev. 20:165–170. 1996. View Article : Google Scholar
23.	Marchesi S, Pasqualini L, Lombardini R, Vaudo G, Lupattelli G, Pirro M, et al: Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol. 41:249–253. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Luo CF, Wu X, Hu X, Wu GF, Hu CH and Du ZM: Protective effect of lipid microspheres 1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris: a pilot study. J Cardiovasc Med (Hagerstown). 12:790–794. 2011. View Article : Google Scholar
25.	Taylor CJ, McGaw J, Rigby AS, Threlfall D and Karmel J: Pilot safety study of liposomal prostaglandin (PGE1) in respiratory exacerbations in cystic fibrosis. J Cyst Fibros. 1:90–93. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Mohler E III and Giri J; ACC; AHA: Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Curr Med Res Opin. 24:2509–2522. 2008. View Article : Google Scholar : PubMed/NCBI